SIStockInvestingSI.com

NYSE · BMY · Drug Manufacturers - General

Bristol Myers Squibb (BMY) stock analysis

$61.12−0.91%Data as of Oct 21, 2026
  • BMY lost 0.8% over the past month versus 0.0% for the S&P 500, ranking 329th of 497 S&P 500 stocks.
  • Over 12 months it returned +43.3%, 27.5 points ahead of the S&P 500, and trades 10.2% below its 52-week high.
  • In the last 30 days 8 analysts raised earnings estimates and 4 cut; forward EPS moved +0.9% (+6.9% over 90 days).
  • It sits in the Large pharma segment of the Healthcare Value Chain, where the 1-month median return is −0.7%.
  • The daily chart reads Intermediate downtrend · Decline (since Oct 14, 2026).
Market cap$124.9B
12-month return+43.3%
Forward P/E9.3×
Mean target vs price+7.4%

One-year price with 50- and 200-day averages

Open in Hub
44.651.858.966.1JanAprJulOct
61.1250-day200-day

Performance vs the market

Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.

BMY−0.8%
Sector median−8.7%
S&P 5000.0%
BMY−0.6%
Sector median−5.4%
S&P 500+4.7%
BMY+3.9%
Sector median−1.5%
S&P 500+8.7%
BMY+43.3%
Sector median+1.7%
S&P 500+15.8%
1-month rank in the S&P 500329 / 497
3-month rank in its sector · Healthcare315 / 720

Chart structure

Read by our daily-bar structure engine from swing highs, swing lows and moving averages.

Intermediate downtrend · DeclineConfirmed

Holding since Oct 14, 2026

  • Price and averages have mixed alignment
  • EMA50 fell over the last ten sessions
  • Confirmed swing highs and lows are rising
  • Some swings conflict with the averages
  • Intermediate and long-term directions differ
This pattern on this stock

86 occurrences in 10 years. The median move over the next 20 sessions was −1.3%, positive 44% of the time, against +0.6% for any day in the same period.

Reference zone, stop and targets for this structureSee the trade plan in Hub ↗

Analyst earnings revisions

Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.

Forward EPS$6.62
30-day change+0.9%
90-day change+6.9%
Mean target$65.63 +7.4%
Raised (30d) 8Cut (30d) 4

24 analysts cover the stock

Fundamental shape vs peers

Six dimensions on fixed scales. The filled shape is the company; the outline is the peer average.

Open the full Radar with every ratio
ValuationRevisionsMomentumGrowthCashProfit

Ahead of peersCash, Growth

Behind peersValuation, Momentum

PeersLLY · JNJ · ABBV · MRK

Where it sits in the supply chain

Healthcare Value Chain · Drugs & devices

Explore the full chain map in Hub
Supplied by
Life-science tools & bioprocessing+6.0%
TMO+5.4%1 monthDHR+6.0%1 monthA+6.4%1 month
Clinical research outsourcing+8.0%
IQV+2.4%1 monthFTRE+17.8%1 monthICLR+10.9%1 monthMEDP+5.1%1 month
Its segment
Large pharma−0.7%
JNJ−4.2%1 monthMRK−0.7%1 monthABBV+7.4%1 monthPFE+6.9%1 monthBMY−0.8%1 month

Oncology, immunology and vaccines, facing patent expiries and US price negotiation; policy news often moves the group together.

Sells into
Drug distribution+13.9%
MCK+13.9%1 monthCOR+8.3%1 monthCAH+16.2%1 month
Government programs & policy

Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps

Risk profile

Max drawdown, 12M−16.8%
Volatility, 60D27.7%
From 52-week high−10.2%
From 52-week low+46.7%
Trailing P/E13.5×
Forward P/E9.3×

Themes

  • Gene/Cell Therapy3M rank 51 / 99
JNJJohnson & JohnsonMRKMerckABBVAbbViePFEPfizerTMOThermo Fisher ScientificDHRDanaherAAgilent Technologies, Inc.IQVIQVIA Holdings, Inc.

Track this stock every day

Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.

Open in Hub ↗